In Vivo Efficacy of SPR206 in an Immunocompetent Murine Ascending UTI Infection Model Caused by Escherichia coli Posted on April 24, 2018 at 2:54 pm.Written by Spero Therapeutics View Presentation Post navigation Activity of Investigational Polymyxin-B-like Compound (SPR206) Against Set of Enterobacteriaceae Organisms Responsible for Human InfectionsIn Vivo Efficacy of SPR206 in Murine Lung and Thigh Infection Models Caused by Multi-Drug Resistant Pathogens Pseudomonas aeruginosa and Acinetobacter baumannii
